A.P. Pharma at
a Glance

Biochronomer™ Technology

  • Formulation flexibility
  • Ease of administration
  • Controlled drug delivery
Welcome to A.P. Pharma

A.P. Pharma, Inc. (OTCBB:APPA.OB) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of the New Drug Application (NDA) for APF530, and has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013.

Recent News

May 10, 2013

A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress

May 2, 2013

A.P. Pharma Appoints New Management Team

March 28, 2013

A.P. Pharma Receives FDA Complete Response Letter for APF530

March 1, 2013

A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress

More News